06/05/23 7:00 AMNasdaq : BVXV low floatBiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisBroad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis. BiondVax to lead development and commercialization of NanoAbs withRHEA-AIpositive
05/15/23 4:45 PMNasdaq : BVXV earningslow floatBiondVax Announces First Quarter 2023 Financial Results and Provides Business UpdateBiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, todayRHEA-AIneutral
04/20/23 5:45 AMNasdaq : BVXV covid-19low floatUnited States Influenza Vaccines Market Analysis Report 2023: COVID-19/Influenza Combination Vaccines Gaining Momentum with GSK, CureVac and Novavax's Continued AdvancementsThe influenza vaccines market in the United States was valued at US$ 3,962 million in 2022 and is expected to reach US$ 8,347 million by 2031, registering a CAGR of 8.6% during the forecast period. This report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size,...RHEA-AIneutral
04/17/23 4:25 PMNasdaq : BVXV low floatBiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmuneRHEA-AIpositive
03/16/23 1:10 PMNasdaq : BVXV conferenceslow floatBiondVax to Present at BIO-Europe Springvia InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmuneRHEA-AIneutral
02/02/23 2:15 PMNasdaq : BVXV low floatBiondVax Presenting at BIO CEO & Investor Conferencevia InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmuneRHEA-AIvery positive
01/23/23 6:25 AMNasdaq : BVXV low floatBiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyCOVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data indicated NanoAbRHEA-AIneutral
01/06/23 7:15 AMNasdaq : BVXV covid-19low floatBiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyHamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo Result builds on recently announced data indicating NanoAb treatment led toRHEA-AIneutral
01/05/23 7:00 AMNasdaq : BVXV conferenceslow floatBiondVax to Present at Biotech Showcase 2023via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases,RHEA-AIvery positive
12/30/22 7:30 AMNasdaq : BVXV low floatBiondVax CEO Issues Letter to Shareholdersvia InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases, todayRHEA-AIpositive